The Unexpected Triumph of Novo Nordisk: A Dividend Hunter’s Delight

by

Viking Therapeutics (VKTX) had quite the disastrous morning on Tuesday, as its stock plummeted a rather alarming 40%. The catalyst? The much-ballyhooed GLP-1 weight-loss pill, VK2735, failed to live up to the hype. But for those who are fond of the finer things, namely dividends and sensible investments, this calamity has been a stroke of luck for another pharmaceutical giant.

Novo Nordisk (NVO), with its impeccable timing, saw its stock rise a modest 2.2% by 10:30 a.m. ET. No doubt, those investors in the know had the foresight to take advantage of Viking’s misfortune, for in the cutthroat world of weight-loss drugs, one company’s flounder is another’s opportunity.

Why Viking’s Sorrow Is Novo Nordisk’s Joy

Now, Viking, ever the optimist, was eager to trumpet the results of its Phase 2 VENTURE-Oral Dosing Trial of VK2735. The press release, bless their hearts, made much of the fact that their pill showed “safe and well-tolerated” results, with participants shedding an average of 12.2% of their weight in 13 weeks. Quite the achievement, one might think. But then came the small print: 20% of participants abandoned the trial, citing “uncomfortable side effects.” A little reminder that not all is as it seems in the clinical world. Oh, and let’s not forget the fact that Eli Lilly (LLY) recently unveiled their own GLP-1 pill, which performed nearly as well-11.5% weight loss-making Viking’s results look more like an average performance at a dreary dinner party than the next big thing.

As for Novo Nordisk? Well, their GLP-1 pill-Wegovy, in tablet form, no less-has managed to help patients lose 12% to 13% of their body weight. Just a tad more effective, wouldn’t you say? Their recent studies have certainly earned them a spot at the table of the weight-loss drug elite.

Loading widget...

The Stock of Novo Nordisk: A Buy for the Discerning Dividend Hunter

Now, if we take a moment to consider all the other rather delectable news surrounding Novo Nordisk this week, it’s easy to see why this stock is a prized catch. A partnership with GoodRX to offer Ozempic and Wegovy at discount prices? A cash discount on Ozempic when ordered directly from the company? And let’s not overlook the FDA’s recent approval to use Wegovy in the treatment of liver disease in adults. These developments make it rather clear that Novo is on a roll.

And here’s the kicker for us dividend aficionados: Novo Nordisk’s stock is priced at a mere 14 times trailing earnings-far more reasonable than the extravagant 45 times earnings for Eli Lilly. Not to mention, Viking, tragically, is currently losing money, a situation which, in the world of dividends, is positively unspeakable. The mathematics here are clear: Novo Nordisk represents a rare opportunity for sensible investors who seek solid returns without the eye-watering multiples of their rivals.

In sum, if you’re looking for a reliable dividend-paying stock in the GLP-1 space, you need not look further. Novo Nordisk is, quite simply, the best value around. Even the most discerning dividend hunter would find it hard to resist such a refined and profitable proposition. 🧐

Read More

2025-08-19 19:41